Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glaucoma surgery showdown: new procedure may offer safer option

NCT ID NCT06952153

Disease control Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two surgical procedures for people with primary angle-closure glaucoma: Phaco-GSL (cataract surgery combined with a procedure to open the eye's drainage angle) and trabeculectomy (a standard glaucoma surgery that creates a new drainage pathway). Researchers want to see which one controls eye pressure better and has fewer side effects. About 82 participants will be randomly assigned to one of the two surgeries and followed for a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Phacoemulsification with Goniosynechialysis (Phaco-GSL) and Trabeculectomy with 5FU
What this could lead to
If this trial succeeds, it could show that Phaco-GSL is a safer or equally effective alternative to trabeculectomy for controlling eye pressure in glaucoma patients.
What could go wrong
This is a small, early-stage trial with only 82 participants, so results may not apply to all patients. Both surgeries carry risks like infection, bleeding, or vision changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 82 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 40 years * Peripheral anterior synechiae (PAS) \>180° * Glaucomatous optic neuropathy with visual field loss * Intraocular pressure (IOP) \> 21 mmHg despite medication * Ability to consent and comply with follow-up * Cataract grade 1 to 3 according to LOCS III * Best corrected visual acuity (BCVA) ≥ 0.3 logMAR (equivalent to 20/40 Snellen or worse) Exclusion Criteria: * Very advanced glaucoma (only light perception vision) * Secondary angle-closure etiologies * Prior ocular surgeries or laser peripheral iridotomy (PI) * Allergy to 5-fluorouracil (5-FU), if used postoperatively * Irreversible corneal disease * Chronic corticosteroid use * Poor follow-up compliance * Cataract grade 4 or 5 (LOCS III) * Phacomorphic, phacolytic, or subluxated cataracts

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary angle-closure glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

angle-closure glaucoma primary angle-closure glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary angle-closure glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • HCMC University of Medicine and Pharmacy

    RECRUITING

    Ho Chi Minh City, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.